Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spark Therapeutics nets $128mm through public stock sale

Executive Summary

Spark Therapeutics Inc. (gene therapies for genetic conditions including retinal, liver-related, and neurodegenerative diseases) netted $128mm through the public sale of 3mm common shares (including the overallotment) at $45. Selling stockholder the Children's Hospital of Philadelphia (CHOP) also sold 1mm shares. Some of the proceeds will fund development of preclinical candidate SPK-FVIII (for hemophilia A) and activities related to the future launch of voretigene neparvovec for RPE65-mediated inherited retinal diseases.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies